Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
OBJECTIVE
To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment.


METHODS
PCOS rat model was established by dehydroepiandrosterone induction. The animals were randomly divided into exenatide treatment group (EX group, n = 10), metformin treatment group (MF group, n = 10), PCOS group (PCOS group, n = 9) and normal control group (NC group, n = 10). Histological changes of the ovarian tissues were examined by HE staining. SIRT1 expression in the ovarian tissue was detected by RT-PCR and immunohistochemistry.


RESULTS
Rats in the PCOS group lost their estrous cycle. Histological observation of the ovary showed saccular dilatation of the follicle, decreased number of corpora lutea, fewer layers of granulosa cells aligned loosely, and thickened layer of theca cells. The changes in reproductive hormones and the development of insulin resistance suggested the successful establishment of the animal models. Immunohistochemistry and Q-PCR detected the mRNA and protein expressions of SIRT1 in the ovary tissues of rats in the normal control group. The SIRT1 expression was significantly lower in PCOS group than in control group (P < 0.05); after drug intervention, the SIRT1 expression significantly increased in EX and MF groups (compared with the PCOS group), whereas no significant difference was noted between the EX group and MF group.


CONCLUSIONS
The SIRT1 expression in the ovary tissue decreases in PCOS rats (compare with the normal rats) but can be up-regulated after Ex or MF treatment. These drugs may affect the process and development of PCOS by regulating the SIRT1 expression. Exenatide may be therapeutic for PCOS by up-regulating the SITR1 expression.
Center for Reproductive Medicine, The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou 510630, China.
Xin
X
Tao
Center for Reproductive Medicine, The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou 510630, China.
Xiao
X
Zhang
Department of Infertility and Sexual Medicine, The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou 510630, China.
Shu-Qi
SQ
Ge
Department of Infertility and Sexual Medicine, The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou 510630, China.
Er-Hong
EH
Zhang
Department of Infertility and Sexual Medicine, The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou 510630, China.
Bin
B
Zhang
D000818:Animals; D003687:Dehydroepiandrosterone; D004195:Disease Models, Animal; D000077270:Exenatide; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D007150:Immunohistochemistry; D008687:Metformin / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D010455:Peptides / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D056564:Sirtuin 1 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D014688:Venoms / Q000494:pharmacology*
D010455:Peptides; D012333:RNA, Messenger; D014688:Venoms; D003687:Dehydroepiandrosterone; D008687:Metformin; D000077270:Exenatide; C488368:Sirt1 protein, rat; D056564:Sirtuin 1
Polycystic ovary syndrome; dimethyl biguanide; exenatide; ovary; silent information regulator 1